160970-07-0

Basic information

• Product Name: N-tert-Butyloxycarbonyl Silodosin
• Synonyms: N-tert-Butyloxycarbonyl Silodosin
• CAS NO: 160970-07-0
• Molecular Formula: C30H40F3N3O6
• Molecular Weight: 595.6503096
• Product Categories: Amines, Aromatics, Chiral Reagents, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 160970-07-0.mol

Chemical Properties

• Boiling Point: 663.7±55.0 °C(Predicted)
• Appearance: /
• Density: 1.237±0.06 g/cm3(Predicted)
• Solubility: Dichloromethane, Ethyl Acetate, Tetrahydrofuran
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: N-tert-Butyloxycarbonyl Silodosin(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-Butyloxycarbonyl Silodosin(160970-07-0)
• EPA Substance Registry System: N-tert-Butyloxycarbonyl Silodosin(160970-07-0)

Safety Data

• Hazardous Substances Data: 160970-07-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-tert-Butyloxycarbonyl Silodosin is used as an intermediate compound for the synthesis of Silodosin, which is an α1a-adrenoceptor antagonist. The application reason is to facilitate the development of pharmaceuticals targeting the α1a-adrenoceptor, which can be used in the treatment of various conditions such as benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
Additionally, the protected form of Silodosin may be used in research and development to study the interactions of α1a-adrenoceptor antagonists with their target receptors, potentially leading to the discovery of new therapeutic agents with improved efficacy and reduced side effects.

Upstream product

• 1427271-99-5 (R)-tert-butyl(1-(7-cyano-1-(3-hydroxypropyl)indolin-5-yl)propan-2-yl)(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 160970-54-7 silodosin 

Downstream Products

• 160970-54-7 silodosin 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF INDOLINE COMPOUND

The present invention relates to an improved process for the preparation of Silodosin (I) which is useful in the treatment of Benign Prostate Hyperplasia (BPH) and related disorders. The present invention also relates to the purification process resulting in substantially pure Silodosin.

Indole derivatives and medicinal compositions containing the same

The present invention relates to indole derivatives represented by the general formula: (wherein R represents an ethyl group or a 2,2,2-trifluoroethyl group; Y represents a hydroxy group or a pivaloyloxy group; and the carbon atom marked with (R) represents a carbon atom in (R) configuration) and pharmaceutically acceptable salts thereof, which have potent and prolonged reducing effects on intraocular pressure and are useful as agents for lowering intraocular pressure.

1,5,7-trisubstituted indoline compounds and salts thereof

Indoline compounds represented by the formula: STR1 wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.